New data from Janssen presented at the Annual European Congress of Rheumatology (EULAR 2019) shows sustained clinical benefit and reduction in severe flares with Stelara® (ustekinumab) in patients with systemic lupus erythematosus (SLE)

June 13, 2019

133

MADRID–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson presented this week results of two analyses from a Phase 2 study of Stelara®* (ustekinumab) in systemic lupus erythematosus (SLE). The studies highlight not only the sustained clinical benefit of ustekinumab – an anti-interleukin (IL) IL-12/23 p40 neutralising monoclonal antibody – on SLE disease activity at one-year, but also show a reduction in the rate of severe flares. They also provide new insights into …

http://www.businesswire.com/news/home/20190613005277/en/New-data-Janssen-presented-Annual-European-Congress/

The Pharmaceutical Marketing Group

Targeting the Tumor Microenvironment

Why Pharma Needs to Care About Global Warming

Business Plan: a Medical Affairs perspective

Rare Diseases at Roche: Combining science and alliances to find breakthroughs in rare diseases

British baby’s death not due to SMA gene therapy: Novartis

GSK’s over-the-counter nicotine oral spray gets FDA panel backing

With a backup to the backup, insulin makers say they’re primed for Brexit

Factbox: Britain’s insulin providers prepare for Brexit fallout

AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen

New data from Janssen presented at the Annual European Congress of Rheumatology (EULAR 2019) shows sustained clinical benefit and reduction in severe flares with Stelara® (ustekinumab) in patients with systemic lupus erythematosus (SLE)